8-K: N2OFF Rebrands to Nexentis, Pivots to AI Biotech

N2OFF, Inc. announces a corporate rebranding to Nexentis Technologies Inc. and a strategic pivot to an AI and data-driven computational biotech platform.

Summary

• N2OFF, Inc. has changed its corporate name to Nexentis Technologies Inc. and its Nasdaq trading symbol from NITO to NXTS.
• The name and symbol changes will take effect on the Nasdaq Capital Market on February 26, 2026.
• The rebranding reflects a strategic transformation into an innovative AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology, and inflammatory metabolic diseases.
• The company completed the acquisition of MitoCareX Bio Ltd. on October 20, 2025, which is now a wholly-owned subsidiary.
• MitoCareX brings a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure-guided virtual screening workflows.
• Preliminary in vitro findings from MITOLINE-derived small-molecule candidates showed reduced key pro-inflammatory markers in human immune cells.
• The company intends to build a diversified pipeline of first-in-class small-molecule programs.
• N2OFF will continue to selectively manage its RTB (Ready to Build) solar energy investments as a non-core, value-optimizing asset base.
• The company also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive strategic pivot into a high-growth, innovative sector (AI-driven biotech), which could unlock significant future value. The rebranding and focus on a proprietary discovery platform are encouraging, though the early stage of the biotech pipeline introduces inherent risks.

Positives

• The strategic pivot to an AI and data-driven computational biotech platform positions the company in a high-growth, innovative sector.
• The acquisition of MitoCareX Bio Ltd. provides a proprietary discovery engine (MITOLINE algorithm) for drug discovery.
• Validation of the MITOLINE platform with in vitro data demonstrating anti-tumor activity and target engagement, as well as reduced pro-inflammatory markers in human immune cells.
• Targeting inflammatory metabolic disease markets projected to exceed $120 billion by 2030 presents significant growth potential.
• The rebranding is expected to enhance strategic clarity and improve alignment with R&D priorities, supporting engagement with partners and collaborators.

Negatives

• The solar energy investments are now considered non-core assets, indicating a reduced focus on this segment.
• The company's biotech pipeline is still in the preclinical stage, with no immediate revenue generation from drug development expected.

Risks

• Market and other conditions may impact operations.
• History of losses and need for additional capital to fund operations, with potential inability to obtain capital on acceptable terms.
• Uncertainties of cash flows and inability to meet working capital needs.
• Risks associated with the initiation, timing, progress, and results of preclinical studies, clinical trials, and product candidate development efforts.
• Ability to advance product candidates into clinical trials or successfully complete preclinical/clinical trials.
• Receipt of regulatory approvals for product candidates and the timing of other regulatory filings and approvals.
• Clinical development, commercialization, and market acceptance of product candidates.
• Ability to establish and maintain strategic partnerships and other corporate collaborations.
• Implementation of the business model and strategic plans for the business and product candidates.
• Scope of protection for intellectual property rights covering product candidates and ability to operate without infringing others' intellectual property.
• Competition from other companies, technologies, and within the industry.
• Risks related to not satisfying the continued listing requirements of the Nasdaq Capital Market.
• Impact of the political and security situation in Israel on the business.

Future Outlook

The company intends to build a diversified pipeline of first-in-class small-molecule programs leveraging its MITOLINE platform, while continuing to manage its RTB solar energy investments as a non-core asset. It is working toward preclinical candidate nominations and aims to translate its in silico and in vitro discoveries into development-ready assets, focusing on the next generation of mitochondrial medicines.

Management Comments

• Management believes the sharpened identity has the potential to enhance strategic clarity, improve alignment with the company's R&D priorities, and support engagement with partners and potential collaborators across the biotech and pharmaceutical ecosystem.

Industry Context

StockSavvy.ai notes that this strategic pivot aligns with a broader industry trend of integrating artificial intelligence and data-driven approaches into biotechnology and drug discovery, particularly in complex areas like mitochondrial biology and precision medicine. The focus on inflammatory metabolic diseases and oncology positions Nexentis in highly competitive but lucrative therapeutic areas, reflecting a move towards high-value, innovation-driven segments.

Corporate Governance

Stakeholder Impact

• Shareholders: Rights are unaffected by the name and symbol change. The strategic pivot could lead to long-term value creation if the biotech pipeline is successful, but also introduces new risks associated with drug discovery.
• Employees: The strategic shift implies a greater focus on biotech R&D, potentially impacting roles and skill sets within the company.
• Customers/Partners (Solar Energy): Existing solar energy partners may see a reduced strategic focus from the company, as these assets are now considered non-core.
• Potential Collaborators (Biotech): The sharpened identity and focus on AI-driven biotech are intended to enhance engagement with partners and collaborators in the biotech and pharmaceutical ecosystem.

Next Steps

• Further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications.
• Working toward preclinical candidate nominations.
• Translating in silico and in vitro discoveries into development-ready assets.

Key Dates

Recommendation

The strategic pivot to AI-driven biotech and rebranding to Nexentis Technologies Inc. represents a significant shift with high potential upside in a growing market. However, the biotech pipeline is in early preclinical stages, carrying substantial development and regulatory risks. While the long-term outlook is promising, the immediate impact is speculative, warranting a 'hold' recommendation for investors to observe progress in the new strategic direction and pipeline development before making more aggressive moves.

Keywords

Biotechnology, AI-driven drug discovery, Mitochondrial biology, Precision oncology, Inflammatory metabolic diseases, MITOLINE algorithm, SLC25 carrier family, Drug development, Corporate rebranding, Nasdaq